US 2021/0228729 A1Published application

Lgals3bp antibody-drug-conjugate and its use for the treatment of cancer

AssigneeMediapharma S.R.L.

InventorsEmily CAPONE, Francesco GIANSANTI, Rodolfo IPPOLITI, Roberta GENTILE, Stefano IACOBELLI, Enza PICCOLO, Sara PONZIANI, Gianluca SALA

Life of this patent

Estimating the term…

patentgrep

Loading patent…

Abstract

The present invention relates to a special type of non-internalizing binding moiety-drug-conjugates that specifically target LGALS3BP. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to LGALS3BP, said antibody being conjugated to cytotoxic drugs. The invention also comprises methods of the treatment of LGALS3BP-expressing cancer, including administering to a patient the disclosed drug conjugates and pharmaceutical preparations.

Claims20

Dependent claims

A targeted therapeutic agent of the formula:

B-D
or a pharmaceutically acceptable salt thereof, wherein
B is a non-internalizing binding moiety specific for a cancer associated protein;
and
D is a cytotoxic drug moiety.

2 more elements

Dependencies are inferred from the claim text.

Facts

Application: 17/046,832Filed 12 Apr 2019
Priority: EP 18166980.512 Apr 2018
Published: 29 Jul 2021
Term ends: Not estimatedThe source records don’t support an estimate.

Classification10 codes

A61K 47/6849
The modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site: the antibody targeting a receptor, a cell…
A61K 31/5365
Having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines: ortho- or peri-condensed with…
A61K 47/68033
Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates: the drug being a maytansine
A61P 35/00
Antineoplastic agents